A recent study found that the cell lines most commonly used for research on ovarian cancer are not the most suitable.

In an eagerly awaited study, Memorial Sloan-Kettering researchers report on the molecular structure of mTOR, a protein commonly mutated in cancer.

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

At the seventh annual seminar for high school students and teachers, investigators discuss how cutting-edge biomedical research may ultimately contribute to better treatments for cancer patients.

Scientists have identified genes and biological mechanisms that one day could be targeted with drugs to stop kidney cancer from spreading to the bone, brain, or other organs.

In the lab of cancer biologist Scott Lowe, researchers are investigating the processes that naturally inhibit cancer development.

Memorial Sloan-Kettering researchers have discovered a way that cancer cells may be able to exchange information by establishing long bridges between cells called tunneling nanotubes.